OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer – a ctDNA-guided phase II randomised approach. Study protocol

References

• Boysen AK, Spindler KLG, Høyer M, et al. Metastasis directed therapy for liver and lung metastases from colorectal cancer – a population-based study. Int J Cancer. 2018;143(12):3218–3226.
   PubMed Web of Science ®Google Scholar
• Nosher JL, Ahmed I, Patel AN, et al. Non-operative therapies for colorectal liver metastases. J Gastrointest Oncol. 2015;6(2):224–240.
   PubMedGoogle Scholar
• Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379(18):1754–1765.
   PubMed Web of Science ®Google Scholar
• Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review. J Clin Oncol. 2018;36(16):1631–1641.
   PubMed Web of Science ®Google Scholar
• Boysen AK, Pallisgaard N, Andersen CSA, et al. Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer. Acta Oncol. 2020;59(12):1424–1429.
   PubMed Web of Science ®Google Scholar
• Hamfjord J, Guren TK, Glimelius B, et al. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. Int J Cancer. 2021;149(6):1385–1397.
   PubMed Web of Science ®Google Scholar
• Spindler KLG, Pallisgaard N, Vogelius I, et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012;18(4):1177–1185.
   PubMed Web of Science ®Google Scholar
• Thomsen CB, Andersen RF, Lindebjerg J, et al. Correlation between tumor-specific mutated and methylated DNA in colorectal cancer. J Clin Oncol Precis Oncol. 2019;3:1–8.
   PubMed Web of Science ®Google Scholar
• Thomsen CB, Hansen TF, Andersen RF, et al. Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer. Ther Adv Med Oncol. 2020;12:1758835920918472.
   Web of Science ®Google Scholar
• Roperch JP, Incitti R, Forbin S, et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 2013;13:566.
   PubMed Web of Science ®Google Scholar
• Garrigou S, Perkins G, Garlan F, et al. A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker. Clin Chem. 2016;62(8):1129–1139.
   PubMed Web of Science ®Google Scholar
• Mise Y, Imamura H, Hashimoto T, et al. Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases. Ann Surg. 2010;251(5):902–909.
   PubMed Web of Science ®Google Scholar
• Serrano PE, Gu CS, Husien M, et al. Risk factors for survival following recurrence after first liver resection for colorectal cancer liver metastases. J Surg Oncol. 2019;120(8):1420–1426.
   PubMed Web of Science ®Google Scholar
• Mitry E, Fields ALA, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26(30):4906–4911.
   PubMed Web of Science ®Google Scholar
• Langer B, Bleiberg H, Labianca R, et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): result of the ENG (EORTC/NCIC CTG/GIVIO). Proc Am Soc Clin Oncol. 2002;21:149.
   Google Scholar
• Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24(31):4976–4982.
   PubMed Web of Science ®Google Scholar
• Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999;64(1):218–224.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990.
   PubMed Web of Science ®Google Scholar
• Henriksen TV, Reinert T, Christensen E, et al. The effect of surgical trauma on circulating free DNA levels in cancer patients—implications for studies of circulating tumor DNA. Mol Oncol. 2020;14(8):1670–1679.
   PubMed Web of Science ®Google Scholar